Louisiana State Employees Retirement System Makes New $2.37 Million Investment in Edwards Lifesciences Corporation $EW

Louisiana State Employees Retirement System bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the first quarter, HoldingsChannel reports. The institutional investor bought 29,600 shares of the medical research company’s stock, valued at approximately $2,370,000.

Several other hedge funds also recently modified their holdings of the business. State Street Corp grew its position in shares of Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after buying an additional 371,892 shares during the period. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after acquiring an additional 989,533 shares during the last quarter. Norges Bank bought a new position in Edwards Lifesciences in the fourth quarter valued at approximately $803,686,000. Morgan Stanley grew its holdings in Edwards Lifesciences by 12.4% during the 4th quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock worth $623,544,000 after acquiring an additional 804,942 shares during the period. Finally, Marshall Wace LLP grew its holdings in Edwards Lifesciences by 66.1% during the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after acquiring an additional 2,359,128 shares during the period. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on EW. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Barclays reaffirmed an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Robert W. Baird upped their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.96.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 620 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the transaction, the vice president directly owned 40,411 shares of the company’s stock, valued at approximately $3,278,948.54. The trade was a 1.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 81,038 shares of company stock worth $6,683,255 over the last three months. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

Shares of EW opened at $91.33 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The stock has a 50 day simple moving average of $84.66 and a 200 day simple moving average of $83.31. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $92.88. The firm has a market capitalization of $52.59 billion, a PE ratio of 48.58, a P/E/G ratio of 2.28 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period last year, the company posted $0.64 EPS. The business’s quarterly revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.